Lydia Lane, MD
Ophthalmology · Little Rock, ARNPI 1033112420
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,228 of the $2,044 with a category attached, or 60.1%. AbbVie accounts for 66.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $984 and has fallen 81.6% since, to $181 in 2025.
Across 50 payments — averaging $40.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$261
- Bausch & Lomb Americas Inc.$108
- Biotissue Holdings Inc.$72
- NEW World Medical,inc.$57
- Aerie Pharmaceuticals, Inc.$50
- plus $143 from 4 others
What the payments were for
- Travel & lodging$81640%
- Food & beverage$1,22860%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $1,353 |
| Alcon | 10 | $261 |
| Bausch & Lomb Americas Inc. | 5 | $108 |
| Biotissue Holdings Inc. | 1 | $72 |
| NEW World Medical,inc. | 1 | $57 |
| Aerie Pharmaceuticals, Inc. | 2 | $50 |
| Rxsight Inc | 2 | $44 |
| Thea Pharma Inc. | 2 | $43 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $32 |
| Novartis | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN$941
- Precision 1$121
How this compares
$2,044 in reported general payments places this provider in the 75th percentile of 125 ophthalmology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 149 | $58,022 |
| CombiganBrimonidine Tartrate/Timolol | 122 | $48,534 |
| Travoprost | 326 | $37,425 |
| Latanoprost | 2,655 | $28,109 |
| Prednisolone Acetate | 553 | $23,964 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 143 | $22,246 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,263 | $19,824 |
| Alphagan PBrimonidine Tartrate | 58 | $19,260 |
| RocklatanNetarsudil Mesylat/Latanoprost | 36 | $16,422 |
| RestasisCyclosporine | 21 | $14,400 |
| VyzultaLatanoprostene Bunod | 44 | $14,099 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 47 | $13,335 |
| Brimonidine Tartrate | 937 | $12,143 |
| Timolol Maleate | 1,098 | $9,972 |
| RhopressaNetarsudil Mesylate | 20 | $6,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $1,353 | $140,215350 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $50 | $22,72656 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $108 | $14,09944 claims |
| AlconSimbrinza | $261 | $13,33547 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 125 ophthalmology providers in Arkansas.
Other ophthalmology in Little Rock
- Jennifer DoyleLittle Rock$38K
- Jonathan CascianoLittle Rock$4K
- Christian HesterLittle Rock$4K
- Sami UwaydatLittle Rock$4K
- Daniel KimLittle Rock$2K
- Justin LieblongLittle Rock$2K
- Kent ZocchiLittle Rock$2K
- Richard MorshediLittle Rock$2K
- Susan BlairLittle Rock$2K
- Tom KornhauserLittle Rock$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.